At the 4^(th)Annual Meeting of the Chinese Alliance for Societies of Hematology(CASH)on January 7,2024,the“China’s Top 10 achievements in hematology in 2023”were unveiled.This prestigious selection,initiated by the...
Chimeric antigen receptor(CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies,with 9 CAR-T-cell products currently available.Furthermore,CAR-T cells have shown promisi...
In January 2023,the hematology community in China came together for the 3rd Annual Meeting of the Chinese Alliance for Societies of Hematology(CASH).It was also the third time to announce China’s top 10 hematologic a...
The China’s top 10 hematological advances in 2021 was announced at the 2nd Annual Meeting of Chinese Alliance for Societies of Hematology on January 16,2022.
The Convergence of Hematology and Immunology(CHI),which was sponsored by State Key Laboratory of Experimental Hematology,Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences(CAMS),wa...
Chimeric antigen receptor(CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies.However,treatment-related toxicity and side effects remain the major drawbacks.As an importan...
Blood system is unique among all the systems and organs in the body.Measurable changes in blood not only reflect blood disorders(including genetic blood diseases,acquired bone marrow failure,and hematological malignan...